Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 10mg.
Most sexual-function medicines act on blood vessels. PT-141 is studied because it acts on receptors in the brain instead, and one formulation became a registered medicine.
PT-141 (bremelanotide) is a synthetic cyclic seven-amino-acid peptide derived from alpha-MSH that activates melanocortin receptors, including MC4R in the brain. It is studied because it addresses the central, desire-related side of sexual response rather than blood flow. Evidence includes randomised phase 3 trials in premenopausal women with hypoactive sexual desire disorder, the basis of a US approval limited to that group; the clinical mechanism is described by the regulator as unknown.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 10mg | P41 | In stock | $80 |
No batch-specific test report is currently published for this product. What a report does and does not show.
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
Bremelanotide is not an approved medicine in Australia and is not separately listed in the Poisons Standard (June 2026). In the United States, Vyleesi (bremelanotide injection) is FDA-approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder, and is expressly not indicated for men, postmenopausal women or enhancing sexual performance.
Status checked 2026-09-23. Details and sources in the research note.